spacer
home > pmps > summer 2018 > driving digitalisation
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Driving Digitalisation

Pharmaceutical manufacturers are faced with the task of bringing new drugs to market as quickly as possible, without any compromise on quality or patient safety. A key driver of this demand is the time pressure faced in relation to the expiry of patents. Therefore, manufacturers need to move from R&D to production in the shortest possible time with minimum investment. Digitalisation and the adoption of emerging industrial digital technologies are set to play key parts in the delivery of such objectives.

Digitalisation is the technology focus behind Industry 4.0, and the central message about how it can enhance manufacturing and production capabilities is gaining steady traction. Advocates say its data-driven, highly connected world of seamless technology platforms will drive productivity improvements, promote agile production, aid competitiveness, and, ultimately, build business value and boost economic success.

The recent publication of the government-backed Made Smarter Review has set out a clear road map for the wide-scale adoption of emerging industrial digitalisation technologies and articulates how this can have a significant and positive economic impact. This includes a predicted £455 billion boost for the UK’s manufacturing base, an increase in manufacturing sector growth of up to 3% per annum, a net gain of 175,000 jobs, and a reduction of CO2 emissions by 4.5%.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Alwyn Jones has over 20 years’ experience in automation and engineering, working with market-leading companies, supplying systems and solutions into the highly regulated industry sectors. At Siemens, he is Head of Pharmaceutical and Life Sciences and manages the UK and Ireland pharmaceutical and life sciences sector strategy, helping manufacturers bring new and affordable drugs to market in the shortest possible time, without any compromise on quality.
spacer
Alwyn Jones
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Clinical and Regulatory Operational Excellence Forum

1. Innovative technologies are expected to take clinical development, licensing, and other regulatory processes to the next level in the future. What do you see are the biggest challenges facing companies when trying to cope with continued data growth in a fast changing environment? Pharmaceutical companies are heavily regulated and introducing change needs proof of acceptance by the authorities. The chance that authorities do not agree with that change makes the industry risk averse. Changes in a stable GxP environment are almost by default seen as a risk, however, not adapting to new technologies should also be seen as a risk! Therefore, ICH developed the ICH Q8, Q9, Q10, Q11, and Q12 guidelines, to anticipate change and implement changes much faster, with less of a regulatory burden. Nevertheless, industry is not picking up with the desired pace. Why not?
More info >>

White Papers

Clinical Trials in Ukraine: Orange Paper Overview and 1st Half Year 2014

Synergy Research Group

The Orange Paper is an analytical report about the clinical trials market in Russia, published quarterly by the contract research organization Synergy Research Group. The first edition of Orange Paper was released in 2006, and at the moment 31 issues have already published. Now, thanks to Synergy Group Ukraine, obtaining information about the market of clinical trials in Ukraine has become possible. In Ukraine, during the period from 1996 to 2013, applicants had obtained 3,864 positive conclusions about the possibility of conducting clinical trials of drugs, both for domestic and foreign manufacturers, including conduct of multinational multi-center clinical trials (hereinafter – MMCTs)
More info >>

 
Industry Events

Cell Therapy Manufacturing & Gene Therapy Congress

4-6 December 2018, RAI, Amsterdam

Bringing together 300+ leaders and key influencers from pharma and biotech companies on 4 - 6 December 2018 in Amsterdam, Cell Therapy Manufacturing & Gene Therapy will provide you with the latest advice for transforming innovative research to prosperous cell & gene therapy manufacturing.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement